7 completed, 5 recruiting, 4 active not recruiting, 3 terminated. 9 Phase 2, 5 Phase 1, 4 Phase 3, 2 Phase 4.
Follow Tenosynovial Giant Cell Tumor: new trials by email Literature Review of Tenosynovial Giant Cell Tumor trials Research Report on Tenosynovial Giant Cell Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT DCC-3014 - Tenosynovial Giant Cell Tumor | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 18 | 2026-10-31 | 2026-09-22 |
| Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) Pimicotinib - Tenosynovial Giant Cell Tumor | Phase 2 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 20 | 2026-03-26 | 2026-09-10 |
| Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery Indocyanine Green - Tenosynovial Giant Cell Tumor | Phase 4 | Recruiting | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 40 | 2026-01-02 | 2026-01-05 |
| MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib Tenosynovial Giant Cell Tumor | Recruiting | Deciphera Pharmaceuticals, LLC | 100 | 2025-09-03 | 2026-07-27 | |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Pimicotinib(ABSK021), Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Abbisko Therapeutics Co, Ltd | 94 | 2023-04-27 | 2026-05-04 |
| A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT AMB-05X - Pigmented Villonodular Synovitis, TGCT | Phase 2 | Completed | AmMax Bio, Inc. | 20 | 2023-01-26 | 2024-07-05 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor Vimseltinib, Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 123 | 2021-10-14 | 2026-03-20 |
| A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 2 | Terminated | AmMax Bio, Inc. | 4 | 2021-09-16 | 2024-05-24 |
| An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS) | Phase 2 | Completed | AmMax Bio, Inc. | 11 | 2021-05-25 | 2024-06-27 |
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 2 | Completed | Daiichi Sankyo Co., Ltd. | 9 | 2021-03-15 | 2026-06-24 |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment TURALIO™ - Hepatotoxicity, Tenosynovial Giant Cell Tumor | Recruiting | Daiichi Sankyo | 30 | 2021-01-07 | 2025-10-06 | |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 4 | Completed | Daiichi Sankyo | 32 | 2020-10-20 | 2024-12-30 |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 3 | Active not recruiting | Daiichi Sankyo Co., Ltd. | 40 | 2020-09-25 | 2026-06-26 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor ABSK021 - Neoplasms, Tenosynovial Giant Cell Tumor | Phase 1 | Recruiting | Abbisko Therapeutics Co, Ltd | 276 | 2020-01-20 | 2026-03-19 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor PLX73086 - Solid Tumors, Tenosynovial Giant Cell Tumor | Phase 1 | Terminated | Plexxikon | 11 | 2016-02-01 | 2018-08-02 |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1 / Phase 2 | Completed | Five Prime Therapeutics, Inc. | 66 | 2015-06-01 | 2021-08-31 |
| Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) Pexidartinib, Placebo - Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath | Phase 3 | Completed | Daiichi Sankyo | 120 | 2015-05-11 | 2022-05-11 |
| Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors PLX7486 TsOH - Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations | Phase 1 | Terminated | Plexxikon | 59 | 2013-08-01 | 2018-08-02 |
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor nilotinib - Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | Phase 2 | Completed | Andrew J. Wagner, MD, PhD | 17 | 2010-09-01 | 2026-02-20 |
Giant Cell Tumor of Tendon Sheath (20) · Synovitis, Pigmented Villonodular (11) · Neoplasms (2) · Joint Diseases (1) · Synovitis (1)
Giant Cell Tumors (20) · Muscular Diseases (20) · Musculoskeletal Diseases (20) · Neoplasms by Histologic Type (20) · Neoplasms, Connective Tissue (20) · Neoplasms, Connective and Soft Tissue (20) · Tendinopathy (20) · Joint Diseases (19) · Synovitis (19) · Neoplasms (18)
pexidartinib (5) · Indocyanine Green (1) · cabiralizumab (1) · nilotinib (1)
AmMax Bio, Inc. (3) · Daiichi Sankyo (3) · Deciphera Pharmaceuticals, LLC (3) · Abbisko Therapeutics Co, Ltd (2) · Daiichi Sankyo Co., Ltd. (2) · Plexxikon (2) · Andrew J. Wagner, MD, PhD (1) · Five Prime Therapeutics, Inc. (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Ono Pharmaceutical Co., Ltd. (1) · Shanghai Jiao Tong University Affiliated Sixth People's Hospital (1)
United States (14) · Netherlands (8) · Poland (7) · Australia (5) · Italy (5) · Spain (5) · Canada (4) · China (4) · France (4) · United Kingdom (4) · Hungary (3) · Japan (3) · Germany (2) · Taiwan (2) · Ukraine (2)
Dorothy Nguyen, MD (3) · Andrew J. Wagner, MD, PhD (1) · Maitreyi Sharma, MD (1) · Project Leader (1) · Siqing Fu, MD (1)
PMID 21613624, PMID 27041409, PMID 28057477, PMID 29290809, PMID 31188797, PMID 31229240, PMID 32224746, PMID 32755241, PMID 33289960, PMID 35230489, PMID 35837703, PMID 36001000, PMID 36502615, PMID 37121591, PMID 37178368, PMID 37593881, PMID 38843860, PMID 39287124, PMID 40841499, PMID 41796601, PMID 42132251, PMID 42872549
2014 (1)